ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2423

In Primary Sjogren’s Syndrome (pSS) IL7 Promotes the Crosstalk Between T Lymphocytes and Salivary Gland Epithelial Cells and Participates to IFN Signature

Gaetane Nocturne1, Juliette Pascaud 2, Elodie Rivière 3, Alexandre Virone 4, Anastasia Dupré 2, Vanessa Gauttier 5, Nicolas Poirier 5 and Xavier Mariette 6, 1Université Paris Sud, Le Kremlin Bicetre, France, 2IMVA - IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre, Paris, France, 3IDMIT, CEA - Université Paris Sud - INSERM U1184, Le Kremlin Bicêtre ; Arthritis R&D, France, Paris, France, 4Université Paris Sud, Le Kremlin Bicetre, 5OSE Immunotherapeutics, Nantes, France, 6Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: il7 and lymphocytes, Sjogren's syndrome

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Sjögrenʼs Syndrome – Basic & Clinical Science Poster I

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: pSS is characterized by lymphocytic infiltration of salivary gland epithelial cells (SGEC). This infiltrate is made of T (TL) and B (BL) lymphocytes. SGEC are now known to be active players of the pathogenesis of the disease. Here we aimed to focus on the crosstalk between SGEC and TL in pSS and on the impact of IL7 on this process given the role of IL7 on TL biology.

Methods: IL-7 serum level was assessed in 372 pSS patients and 73 paired controls. Primary cultures of salivary gland epithelial cells (SGEC) from patients and controls were stimulated by Poly I:C 30 ng/ml, IFN-α 600UI/ml, IFN-γ 5ng/ml and IFN-λ (IL-28) 25ng/ml for 72 hours. IL-7 secretion was tested in culture supernatant (SN) by ELISA and by quantitative RT-PCR. Four-day and eight-day co-cultures (allogenic and then autologous) between LT and SGEC were performed in presence of Poly IC and anti-CD3/anti-CD28 and anti IL7-R (OSE-127, 10 µg/ml) or control isotype. TL survival and activation were assessed by FACS. Last, explants from minor salivary gland biopsies (MSGB) from 9 pSS patients and 3 controls were cultured for 4 days in presence of anti IL7-R (OSE-127, 10 µg/ml) or control isotype.  Transcriptomic analysis from the biopsies (explants and cells in the SN) was studied by Nanostring (Immunology panel_v2).

Results: pSS patients had higher serum IL-7 levels than controls: 7.56 ng/ml ± 8.52 (mean ± SD) versus 4.86 ng/ml ± 5.59; p< 0.0001. SGEC stimulation with Poly I:C, IFN-α, -γ and -λ induced IL-7 protein secretion in the supernatant (p=0.002, p=0.004, p=0.007, p=0.004 respectively). IL-7 expression was confirmed by quantitative RT-PCR. Allogenic co-culture lead to increased activation of TL as assessed by increased HLA-DR expression and this was partially inhibited by adding OSE-127 in the co-culture. This activation was not observed in autologous co-cultures. Co-cultures of SGECs with either allogenic or autologous TL showed that TL survival was increased by co-culture and this effect was not abolished by inhibiting IL7 signaling with OSE-127. Lastly, analysis of the mRNA signature from MSGB explants from pSS patients revealed that inhibition of IL7 signaling by OSE-127 lead to a decreased of IFN signature as assessed by decreased expression of IFITM1 and Mx-1 both in the explants and in the cells in the SN (Figure).

Conclusion: This study shows that IL7, a key TL cytokine, is increased in pSS and is locally produced by SGEC after PolyI:C and IFNs stimulation. SGEC are likely to have a feeder effect allowing survival of TL but it seems to be independent of IL7. However and interestingly, IL7 signaling may participate to the IFN signature observed in different glandular cellular sub-types in pSS, as demonstrated by decreased IFN signature after IL7-R inhibition both in the explant and in the cellular SN.

Figure: Volcano plots showing differential expression of the mRNA after exposure to OSE-127


Disclosure: G. Nocturne, None; J. Pascaud, None; E. Rivière, None; A. Virone, None; A. Dupré, None; V. Gauttier, OSE Immunotherapeutics, 3; N. Poirier, OSE Immunotherapeutics, 3; X. Mariette, Biogen, 2, Bristol-Myers Squibb, 5, GlaxoSmithKline, 5, Janssen, 5, LFB Pharmaceuticals, 5, OSE Immunotherapeutics, 2, Pfizer, 2, 5, UCB Pharma, 5, 8.

To cite this abstract in AMA style:

Nocturne G, Pascaud J, Rivière E, Virone A, Dupré A, Gauttier V, Poirier N, Mariette X. In Primary Sjogren’s Syndrome (pSS) IL7 Promotes the Crosstalk Between T Lymphocytes and Salivary Gland Epithelial Cells and Participates to IFN Signature [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/in-primary-sjogrens-syndrome-pss-il7-promotes-the-crosstalk-between-t-lymphocytes-and-salivary-gland-epithelial-cells-and-participates-to-ifn-signature/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/in-primary-sjogrens-syndrome-pss-il7-promotes-the-crosstalk-between-t-lymphocytes-and-salivary-gland-epithelial-cells-and-participates-to-ifn-signature/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology